Literature DB >> 20478986

Multidrug resistant typhoid fever outbreak in Ercek Village-Van, Eastern Anatolia, Turkey: clinical profile, sensitivity patterns and response to antimicrobials.

Adalet Aypak1, Ali Kutta Celik, Cenk Aypak, Oztekin Cikman.   

Abstract

The present study discusses the clinical features and treatment outcomes during an outbreak caused by multidrug resistant (MDR) Salmonella typhi isolates from Van, Turkey. Of the 867 typhoid fever patients from the same village, 154 (17.8%) were hospitalised. A total of 42 (27.3%) cultures were positive. All S. typhi isolates were resistant to chloramphenicol, ampicillin and co-trimoxazole. Ceftriaxone was the most commonly used antibiotic (89%). It was found that the time-to-fever defervescence and the length of the hospital stay were greater for patients who were treated by ciprofloxacin than ceftriaxone (P < 0.001). Inappropriate antibiotic treatment should be discouraged in order to prevent the development of resistant strains of S. typhi.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20478986     DOI: 10.1258/td.2010.090438

Source DB:  PubMed          Journal:  Trop Doct        ISSN: 0049-4755            Impact factor:   0.731


  3 in total

1.  Epidemiological characteristics and molecular typing of Salmonella enterica serovar Typhi during a waterborne outbreak in Eastern Anatolia.

Authors:  Y Bayram; H Güdücüoğlu; B Otlu; C Aypak; N C Gürsoy; H Uluç; M Berktaş
Journal:  Ann Trop Med Parasitol       Date:  2011-07

2.  Analysis of characteristics of paratyphoid A in 157 Chinese inpatients between 1998 and 2009.

Authors:  F Yu; S Fan; X Fan; P Dong; X Wang; Y Chen; J Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-09       Impact factor: 3.267

Review 3.  Typhoid Outbreaks, 1989-2018: Implications for Prevention and Control.

Authors:  Grace D Appiah; Alexandria Chung; Adwoa D Bentsi-Enchill; Sunkyung Kim; John A Crump; Vittal Mogasale; Rachael Pellegrino; Rachel B Slayton; Eric D Mintz
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.